Amgen sets sights on Coherus over biologic drug

12-05-2017

Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.


Amgen, patent, patent infringement, Coherus Biosciences, Neulasta, Biologics Price Competition and Innovation Act, biologics, biosimilars

More on this story

US court dismisses Amgen biologic patent suit
28-03-2018

LSIPR